| Preview | Issue Date | Title / Name | Author(s) |
| Mar-2022 | Health-related quality of life in metastatic hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international randomized phase III trial led by ANZUP | Stockler, M. R.; Martin, A. J.; Davis, I. D.; Dhillon, H. M.; Begbie, S. D.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W. R.; Pook, D. W.; Reaume, M. N.; Sandhu, S.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; ENSAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
| Mar-2026 | High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD) | Nair-Shalliker, V.; Smith, D.P.; Gebski, V.; Patel, M.I.; Frydenberg, M.; Yaxley, J.; Gardiner, R.; Espinoza, D.; Kimlin, M.G.; Dhillon, V.; Leifert, W.; Gillatt, D.; Woo, H.; Rasiah, K.; Awad, N.; Symons, J.; Wells, J.K.; Pickett, H.A.; Fenech, M.; Anderson, P.H.; Armstrong, B.K.; Gurney, H.; Awad, Nader | |
| Mar-2026 | High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD) | Nair-Shalliker, V.; Smith, D. P.; Gebski, V.; Patel, M. I.; Frydenberg, M.; Yaxley, J.; Gardiner, R.; Espinoza, D.; Kimlin, M. G.; Dhillon, V.; Leifert, W.; Gillatt, D.; Woo, H.; Rasiah, K.; Awad, Nader; Symons, J.; Wells, J. K.; Pickett, M.; French, M.; Anderson, P. H.; Armstrong, B. K.; Gurney, H.; Awad, Nader | |
| Mar-2021 | High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial | Nair-Shalliker, V.; Smith, D.P.; Gillatt, D.; Gurney, H.; Patel, M.I.; Woo, H.; Rasiah, K.; Symons, J.; Gebski, V.; Espinoza, D.; Frydenberg, M.; Yaxley, J.W.; Gardiner, R.; Kimlin, M.G.; Fenech, M.; Armstrong, B.K.; Rasiah, K.; Awad, N.; Awad, N. | |
| Oct-2016 | Impact of branding on public awareness of healthcare‐related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand | Gianduzzo, T.R.J.; Gardiner, R.A.; Rashid, Prem; Young, R.; Frydenberg, M.; Kelly, S.; Rashid, Prem | |
| Sep-2021 | Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Begbie, Stephen | |
| Feb-2026 | Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) | Inderjeeth, A-J.; Martin, A.J.; Zielinski, R.R.; Begbie, S.; Cheung, L.; Chowdhury, S.; Frydenberg, M.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.S.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; Pook, D.W.; Reaume, M.N.; Sandhu, S.; Tan, A.; Tan, T.H.; Thomson, A.H.; Vera-Badillo, F.; Williams, S.G.; Thomas, H.; Yip, S.; Zhang, A.Y.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Davis, I.D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.; Begbie, Stephen D. | |
| Apr-2023 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Cheung, L.; Chi, K. N.; Chowdhury, S.; Frydenberg, M.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
